Together, these analyses highlight the importance of understanding the complex interplay between the therapeutically tractable receptors αVβ6 integrin and HER2 and the trafficking regulatory proteins GDI2, RAB5, and RAB7A in breast cancer to predict patient survival and design novel therapeutic strategies for HER2+ breast cancer. Here, RAB5A is linked to breast carcinoma.